Our recent technical analysis of Alzamend Neuro (USA Stocks:ALZN)
 | By Ellen Johnson | Macroaxis Story |
Alzamend Neuro stock has an average 'Buy' rating from two analysts. This consensus is likely based on technical analysis, a method that uses price momentum, patterns, and trends from historical prices. The goal is to identify signals based on the market sentiment of Alzamend Neuro's investors and their perception of the stock's future value. Let's delve into a few aspects of Alzamend's technical analysis.
Main Points
Alzamend Neuro (ALZN) exhibits a promising technical outlook, with a potential upside of 11.74% hinting at the stock's potential for significant price appreciation. The stock's Mean Deviation of 4.26 and Standard Deviation of 6.55 indicate a moderate level of price volatility, which could offer lucrative trading opportunities for risk-tolerant investors. However, investors should also consider the company's financial health, as it reported a loss of $14.9M in Net Income from Continuing Operations. The stock's Beta of 0.026 also suggests a low correlation with the broader market, providing a potential hedge against market volatility.Macroaxis uses a strict editorial review process to publish stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.
Reviewed by Raphi Shpitalnik
A rising tide lifts all boats, and the healthcare sector, particularly biotechnology, is no exception. As of July 26, 2024, Alzamend Neuro (ALZN), a promising player in the NASDAQ exchange, has been making waves. Despite a net income loss of $14.9M and a net interest income loss of $7.7K in the fiscal year ending in April, the company has shown potential for growth. Its Accumulation Distribution figure stands at 3.5K, indicating that more investors are buying the stock than selling it. The 50-day moving average (MA) is at 4.83, while the stock has hit a 52-week high of 72, signaling a bullish trend. Moreover, the Wall Street target price is set at a staggering 210, and the overall analyst consensus recommends a 'Buy'. However, caution is advised as the short percent stands at 0.0333, and the beta is at a low 0.026, indicating a lower correlation with the market. Yet, with the highest estimated target price at 4.44 and a real valuation of 3.83, Alzamend Neuro is a stock that could unlock potential returns for discerning investors. As concerns rise among baby boomers about the biotechnology sector, it's worth reviewing Alzamend Neuro in light of economic and market trends. As previously suggested, Alzamend Neuro is starting to decline as investors become more bearish due to heightened sector volatility. The company's returns are highly sensitive to market fluctuations, suggesting that as the market moves, so too will the company. Stable basic indicators may also suggest potential long-term losses for Alzamend investors. Alzamend Neuro is set to announce its earnings today.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Alzamend Neuro. Your research has to be compared to or analyzed against Alzamend Neuro's peers to derive any actionable benefits. When done correctly, Alzamend Neuro's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Alzamend Neuro.
Using predictive technical analysis, we can analyze different prices and returns patterns and diagnose historical swings to determine the real value of Alzamend Neuro. In general, sophisticated investors focus on analyzing Alzamend Neuro stock price patterns and their correlations with different microeconomic environment and drivers. They apply predictive analytics to build Alzamend Neuro's daily price indicators and compare them against related drivers such as momentum indicators and various other types of predictive indicators. Using this methodology combined with a more conventional technical analysis and fundamental analysis, we attempt to find the most accurate representation of Alzamend Neuro's intrinsic value. In addition to deriving basic predictive indicators for Alzamend Neuro, many experienced traders also check how macroeconomic factors affect Alzamend Neuro price patterns. Please read more on our technical analysis page or use our predictive modules below to complement your research.
Watch out for price decline
Please consider monitoring Alzamend Neuro on a daily basis if you are holding a position in it. Alzamend Neuro is trading at a penny-stock level, and the possibility of delisting is much higher compared to other stocks. However, just because the stock is trading under one dollar, does not mean it will be marked for deletion. Most exchanges require public instruments, such as Alzamend Neuro stock to be traded above the $1 level to remain listed. If Alzamend Neuro stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.
How important is Alzamend Neuro's Liquidity
Alzamend Neuro financial leverage refers to using borrowed capital as a funding source to finance Alzamend Neuro ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Alzamend Neuro financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Alzamend Neuro's owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Alzamend Neuro's financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the breakdown between Alzamend Neuro's total debt and its cash.
Alzamend Neuro Gross Profit
Alzamend Neuro Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Alzamend Neuro previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Alzamend Neuro Gross Profit growth over the last 10 years. Please check Alzamend Neuro's gross profit and other fundamental indicators for more details.
Breaking down Alzamend Neuro Indicators
The company has a beta of 1.0628. As returns on the market increase, Alzamend Neuro's returns are expected to increase less than the market. However, during the bear market, the loss of holding Alzamend Neuro is expected to be smaller as well. The beta indicator helps investors understand whether Alzamend Neuro moves in the same direction as the rest of the market, and how volatile (i.e., risky) it is compared to the market (i.e., selected benchmark). In other words, if Alzamend deviates very little from the market, it does not add much risk to the portfolio, but it also doesn't increase the expected returns.Net Loss for the year was (14.88 M) with profit before overhead, payroll, taxes, and interest of 0. "Never put all your eggs in one basket," is a common saying in finance that rings true when analyzing Alzamend Neuro (ALZN). The company's high standard deviation of 6.55 and a Value at Risk of -9.69 indicate a high level of volatility and potential for significant losses. However, with a target price of $210, there is a potential upside of 11.74, suggesting that the stock could offer substantial returns for risk-tolerant investors. Despite a net income loss of $14.9M, the company maintains a healthy working capital of $2.97M and cash equivalents of $11.53M. Investors should be aware of the high probability of bankruptcy at 96.00%, but also consider the potential returns that could be unlocked with careful risk management..
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Ellen Johnson do not own shares of Alzamend Neuro. Please refer to our Terms of Use for any information regarding our disclosure principles.